Article Details

Open-Label Data vs Real-World Data for Anti-CD20 Therapies in Multiple Sclerosis

Retrieved on: 2024-05-14 13:56:40

Tags for this article:

Click the tags to see associated articles and topics

Open-Label Data vs Real-World Data for Anti-CD20 Therapies in Multiple Sclerosis. View article details on hiswai:

Summary

The article discusses a panel's exploration of using both clinical trial and real-world data to assess the effectiveness and safety of CD20-targeting therapies in multiple sclerosis management, emphasizing the value of integrating diverse data sources in clinical practice.

Article found on: www.neurologylive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up